TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 years of age or older at the time of signing the informed consent form (ICF)~* SBS as a result of major intestinal resection resulting in at least 12 months intravenous feeding~* Body weight must be less than 90 kg~* At baseline, subjects must require PN treatment to meet their caloric or electrolyte needs due to ongoing malabsorption at least 3 times weekly and to be on a stable PN regimen for 4 weeks before dosing~* Body mass index (BMI) 18 to 27 kg/m2~* Adequate hepatic and renal function~Exclusion Criteria:~* History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state~* History of alcohol or drug abuse (within previous year)~* Participation in a clinical study within 30 days prior to signing the ICF, or concurrent participation in any clinical study~* Clinically significant laboratory abnormalities at the time of randomization~* Previous use of teduglutide (ALX-0600)~* Prior use of native GLP-2 within 3 months of screening visit~* Hospital admission within 1 month prior to screening visit~* Pregnant or lactating women~* Any condition or circumstance, which in the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with analysis of the study results.~* Presence of excluded disease: Radiation enteritis, Scleroderma, Celiac disease, Refractory/Tropical sprue, Pseudo-obstruction, Active inflammatory bowel disease (IBD), Pre-malignant/malignant change in colonoscopy biopsy or polypectomy, Surgery scheduled within the time frame of the study, Human immunodeficiency virus (HIV) positive test, Immunological disorders, Possible allergies to teduglutide or its constituents, Significant, active, uncontrolled, untreated systemic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo injectable subcutaneously daily into the thigh or abdomen
- 2 (Type: EXPERIMENTAL): teduglutide 0.05 mg/kg/d
- 3 (Type: EXPERIMENTAL): teduglutide 0.1 mg/kg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 positive by licensed diagnostic test~* aged \>16 years of age (or minimum age as determined by local regulations or as legal requirements dictate)~* 50 \< cluster of differentiation (CD)4 \<500 cells/µL~* No prior AIDS-defining illness, using the Center for Diseases Control 1993 Case Definition (except pulmonary tuberculosis)~* HIV RNA ≥1000 copies/mL~* no prior exposure to antiretroviral therapy (ART) (including short course ART for preventing MTCT)~* calculated creatinine clearance (CLCr) more than or equal to 50 mL/min (Cockcroft-Gault formula)~* provision of written informed consent.~Exclusion Criteria:~* the following laboratory values:~  * absolute neutrophil count (ANC) \<500 cells/μL~ * hemoglobin \<7.0 g/dL~ * platelet count \<50,000 cells/μL~ * alanine aminotransferase and/or aspartate aminotransferase \>5 x upper limit of normal~* pregnant women or nursing mothers~* active opportunistic or malignant disease not under adequate control~* use of immunomodulators within 30 days prior to screening~* use of any prohibited medications~* current alcohol or illicit substance use that might adversely affect study participation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 600 milligram (mg) Efavirenz (Type: ACTIVE_COMPARATOR): Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
- 400mg Efavirenz (Type: EXPERIMENTAL): Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Avastin for Treatment of Corneal Neovascularization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 18 years of age~* Clinical stable corneal neovascularization (as defined above)~* Ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits.~* All female patients of childbearing potential will be excluded. A female is considered to be of childbearing potential unless she is postmenopausal and without menses for 12 months or without a uterus and/or both ovaries.~Exclusion Criteria:~* Current or recent (≤ 1 month) systemic corticosteroid therapy or periocular corticosteroid injections to the study eye~* Current or recent (≤ 3 months) intravitreal drug injection to the study eye; recent (≤ 1 month) change in dose and frequency of topical steroids and/or non-steroidal anti-inflammatory agents~* Uncontrolled hypertension defined as systolic blood pressure of ≥ 150 mmHg or diastolic blood pressure of ≥ 90 mmHg; history of a thromboembolic event, including myocardial infarction or cerebral vascular accident~* Patients age 75 or older; history of renal abnormalities~* Recent (≤ 3 months ) or planned surgery~* History of coagulation abnormalities, including end stage liver disease or current anticoagulation medication other than aspirin (warfarin, heparin, enoxaparin, or similar anticoagulant agent)~* All female patients of childbearing potential (a female is considered to be of childbearing potential unless she is postmenopausal and without menses for 12 months or without a uterus and/or both ovaries)~* Any condition (including language barrier) that precludes patient's ability to comply with study requirements including completion of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Topical Avastin 1.0% (Type: EXPERIMENTAL): Each patient will receive topical Avastin in one eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder~* Veteran~* Engaged in compensated work activity, volunteer work, school~* Age 18 to 70~Exclusion Criteria:~* Currently meet criteria for substance abuse or have met criteria for substance dependence in that previous 6 months~* Have an estimated premorbid IQ below 70,~* Have a history of a clinically significant head injury or neurological disease~* Do not speak English well enough to comprehend testing procedures~* Do not demonstrate adequate understanding of study procedures to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Supported SCIT (Type: EXPERIMENTAL): Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One 2-hour group session will be offered once a week for 12 weeks. In addition, 30 minutes of individual training will be provided weekly by an instructor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Implementing PTSD Treatment in FQHCs for Michigan Medicaid Enrollees

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. receive care at a Michigan CHC~2. have a PCL-5 score ≥33~3. have had psychotropic medication stability for at least 4 weeks~Exclusion Criteria:~1. substantially cognitively impaired (according to the Mini-Cog)~2. unable to agree to study procedures for any reason (including incompetency)~3. at high risk of suicide~4. currently engaged in a trauma-focused behavioral treatment (such as Prolonged Exposure or Cognitive Processing Therapy)~5. unable to speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PE-PC (Type: EXPERIMENTAL): Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥ 4 years and \<10 years of age~* Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 53 to restore the dystrophin mRNA reading frame;~* Able to walk independently without assistive devices;~* Ability to complete the time to stand, time to run/walk and time to climb assessments;~* Stable dose of glucocorticoid for at least 3 months~Exclusion Criteria:~* Acute illness within 4 weeks prior to the first dose of study medication;~* Evidence of symptomatic cardiomyopathy. \[Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary\];~* Severe allergy or hypersensitivity to medications;~* Severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;~* Previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;~* Patient is taking any other investigational drug currently or within 3 months prior to the start of study treatment; or~* Patient has had surgery within the 3 months prior to the first anticipated administration of study medication or surgery is planned for anytime during the duration of the study;~* Patient has previously participated in this study or any other study during which NS-065/NCNP-01 was administered.

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- NS-065/NCNP-01 40mg/kg (Type: EXPERIMENTAL): Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
- NS-065/NCNP-01 80mg/kg (Type: EXPERIMENTAL): Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients with primary malignant tumors of the central nervous system (CNS) excluding subjects with primary CNS lymphoma.~2. Age\> 21 years.~3. There should be a gap of two weeks between the last surgery and/or radiotherapy procedure and the day of randomization. If the procedure were intrabdominal, the gap should be of four weeks.~4. Patients with neutrophils\> 1.5 x 109 / L and platelets\> 100 x 109 / L.~5. Signed written informed consent for participation in the trial.~Exclusion Criteria:~1. Known hypersensitivity to Temozolomide or any other ingredient of the pharmaceutical formulation.~2. Any situation (eg. vomiting) that may interfere with the absorption of the product under study.~3. Chemotherapy or biological therapy within four weeks prior to administering the products under study.~4. Patients who experience any symptoms of toxicity to prior antineoplastic therapies upon administration of the products under study.~5. Participation in other clinical research studies during the 90 days before the start of this study.~6. History of alcohol or drugs abuse.~7. History of severe allergic reactions to any type of antigen.~8. History of gastrointestinal surgery (except uncomplicated appendectomy, of at least three months old).~9. Patients whose clinical status would affect the safety of the products under study or interfere with the pharmacokinetic evaluation, at the discretion of the investigator.~10. Pregnant women or women planning to become pregnant during the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temodal (Type: ACTIVE_COMPARATOR): Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
- Dralitem (Type: EXPERIMENTAL): Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥13 years of age~2. Clinical diagnosis of HoFH AND one of the following (a, b, or c):~   * Documented functional mutation in both LDL receptor alleles, OR~  * Skin fibroblast LDL receptor activity \<20% of normal, OR~  * TC \>500 mg/dL AND triglycerides \< 300 mg/dL AND both parents with documented TC \>250 mg/dL~3. Body weight ≥40 kg~4. Negative screening pregnancy test if female of child-bearing potential~5. Subjects must be willing and able to comply with all study-related procedures~6. Subjects must be willing and able to go off all lipid-lowering medications, dietary supplements (psyllium preparations) and LDL apheresis within 4 weeks prior to the Baseline visit until the end of the study.~Exclusion Criteria:~1. Uncontrolled hypertension defined as: systolic blood pressure \>180 mmHg, diastolic blood pressure \>95 mmHg~2. History of chronic renal insufficiency (serum creatinine \>2.5 mg/dL)~3. History of liver disease or abnormal LFTs at screening (\>3x upper limit of normal \[ULN\])~4. Any major surgical procedure occurring \< 3 months prior to the screening visit~5. Cardiac insufficiency defined by the New York Heart Association classification as functional Class III or Class IV~6. History of a non-skin malignancy within the previous 5 years~7. History of alcohol or drug abuse~8. Participation in an investigational drug study within 6 weeks prior to the screening visit~9. Serious or unstable medical or psychological conditions that, in the opinion of the Investigator, would compromise the patient's safety or successful participation in the study.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lomitapide (Type: EXPERIMENTAL): This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck (SCCHN)~* Recurrent and/or metastatic SCCHN, not suitable for local therapy~Exclusion Criteria:~* Prior systemic chemotherapy, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 6 months prior to study entry~* Surgery (excluding prior diagnostic biopsy), or irradiation within 4 weeks before study entry~* Nasopharyngeal carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab Plus Chemotherapy (Type: EXPERIMENTAL): None
- Chemotherapy alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of ulcerative colitis~Exclusion Criteria:~* a history of allergy or hypersensitivity to salicylates or aminosalicylates;~* a history of extensive small bowel resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
- 2 (Type: EXPERIMENTAL): mesalamine 4.8 g/day (800 mg tablet) for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* females~* with at least 10 cm from the lateral reticular veins of the leg or thigh of the leg~* clinical classification of chronic venous disease C1(mild venous disease),~* minimum age of 18 year-old and maximum age 69 year-old~* agreement with the study~* signing the free and informed consent ( IC)~* not use anticoagulant drugs .~Exclusion Criteria:~* male~* varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease)~* restrict mobility~* arterial insufficiency~* be allergic to any substance that may be related to the study drugs~* any cause of dermatitis on application site~* free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism~* pregnancy~* previous deep vein thrombosis (DVT)~* family history of DVT~* thrombophilia~* do not agree with the search terms

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Polidocanol with Glucose (Type: ACTIVE_COMPARATOR): An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
- Glucose (Type: ACTIVE_COMPARATOR): An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pethema Multiple Myeloma 2000

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Less 70 years~* ECOG 0-2~* Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia, extramedulary plasmocytoma, creatinine \>2 mg/dl).~* No previous chemotherapy~Exclusion Criteria:~* \>70 years~* ECOG 3-4~* myeloma quiescent~* cardiopathy~* liver disfunction~* HIV+~* Hepatitis B-C +~* Previous chemotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 69 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years or older with healthy ocular status and pre-operative refractive anisometropia of less than 2.000 diopters between eyes undergoing bilateral PRK surgery.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Those desiring PRK in only one eye, those in need of additional topical eye medications, those with history of drug/alcohol abuse, women breastfeeding or pregnant.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nevanac (Type: EXPERIMENTAL): One drop, three times daily, in the assigned eye for the first three postoperative days
- Acular LS (Type: PLACEBO_COMPARATOR): One drop, three times daily, in the assigned eye for the first three postoperative days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete